MINNEAPOLIS, MN — The SYMPLICITY HTN-3 trial, a phase 3 study testing catheter-based renal denervation for the treatment of resistant hypertension, failed to achieve its primary efficacy end point, ...
Late-breaking presentation of Explore-CKD trial at ASN Kidney Week – – Pivotal Phase 3 Launch-HTN trial featured in the “Best of JAMA and NEJM” session - RADNOR, Pa., Nov. 07, 2025 (GLOBE NEWSWIRE) -- ...
RADNOR, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ...
CHICAGO, IL—In the expanded SPYRAL HTN-ON MED trial, renal denervation with the Symplicity Spyral multielectrode catheter (Medtronic) failed to meet its primary endpoint in terms of blood ...
Please provide your email address to receive an email when new articles are posted on . Once-daily lorundrostat safely lowered 24-hour systolic BP compared with placebo in a phase 2 trial. A ...
Lorundrostat, a hypertension drug from Mineralys Therapeutics, has shown positive results in two pivotal trials for the treatment of uncontrolled or resistant hypertension the company announced on ...
Nurses from all sectors can take a leading role in preventing and controlling hypertension, thereby preventing high rates of cardiovascular disease, new study says. With hypertension (HTN) as a ...
Role of single nucleotide polymorphisms of gemcitabine metabolic genes in metastatic colorectal cancer patients treated with gemcitabine-based salvage therapy. Background: There are no known ...
When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. HTN Communications has renewed its contract with the Major League Baseball (MLB) Network to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback